about
Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease.Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy - is less enough?Infliximab in inflammatory bowel diseaseLetter: infliximab concentrations during induction therapy-one size does not fit allNew role for azathioprine in case of switching anti-TNFs in IBDMaintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel DiseaseBone of Contention: Helicobacter pylori and Osteoporosis-Is There an Association?
P50
Q48170302-EE3597E4-9A18-4881-8D3F-F9B02549ED96Q48230305-EB9A4B18-B8C9-4F95-99DE-8DDB85F3E076Q48288875-825A9645-99B2-4D98-BD70-4EC8E8CEDEDFQ48334518-5933BA63-9F73-471D-8044-F0735089E571Q64121962-52747203-1D2A-4EE2-8BA1-AE3F87C69865Q88337189-99E768A5-CA4C-46E4-9711-26C5229919D3Q89789805-709632CE-4542-4FA9-A704-08BFBEA9B247Q90148632-22FC3541-A7F5-409E-9E5E-07972049BE6FQ92583944-D9E0C182-7609-4DB8-A0AF-FE9B0C7D3257
P50
description
researcher
@en
name
K Papamichael
@en
type
label
K Papamichael
@en
prefLabel
K Papamichael
@en
P31
P496
0000-0003-1497-0254